WEKO3
アイテム
{"_buckets": {"deposit": "5ad0cc4a-b31b-407d-ad47-ff4ef8ec103f"}, "_deposit": {"created_by": 1, "id": "80951", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "80951"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00080951", "sets": ["29"]}, "author_link": ["900478", "900476", "900479", "900477"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2020-11-12", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Liver metastasis (LM) is often found in patients with gastric cancer (GC) and the prognosis is miserable. HER2 is overexpressed in 7-34% of LMGC. Alpha-radioimmunotherapy (α-RIT) is expected to be a promising therapeutic option for metastasis with the combination of cancer specific drug delivery of antibody and high cell cytotoxicity of α-particle. Astatine 211 (At-211) is an attractive α-particle emitter with appropriate half-life and producible with cyclotron.\nWe have investigated the therapeutic efficacy and toxicity of α-RIT with [At-211]-trastuzumab against LMGC using preclinical mice model. A single injection of [At-211]-trastuzumab effectively eradicated LMGC without recurrence in 6/8 mice and significantly prolonged the survival compared to control. There was no severe toxicity observed as long as we monitored.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第60回日本核医学会学術総会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "李, 惠子"}], "nameIdentifiers": [{"nameIdentifier": "900476", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川, 純崇"}], "nameIdentifiers": [{"nameIdentifier": "900477", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Li, Huizi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "900478", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasegawa, Sumitaka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "900479", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "胃がん肝転移に対するα線放射免疫療法の⾮臨床研究", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "胃がん肝転移に対するα線放射免疫療法の⾮臨床研究"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/80951", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-11-13"}, "publish_date": "2020-11-13", "publish_status": "0", "recid": "80951", "relation": {}, "relation_version_is_last": true, "title": ["胃がん肝転移に対するα線放射免疫療法の⾮臨床研究"], "weko_shared_id": -1}
胃がん肝転移に対するα線放射免疫療法の⾮臨床研究
https://repo.qst.go.jp/records/80951
https://repo.qst.go.jp/records/8095125a763c8-6a71-47ec-98c8-a4a0bff0f08e
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-11-13 | |||||
タイトル | ||||||
タイトル | 胃がん肝転移に対するα線放射免疫療法の⾮臨床研究 | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× Li, Huizi× Hasegawa, Sumitaka |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Liver metastasis (LM) is often found in patients with gastric cancer (GC) and the prognosis is miserable. HER2 is overexpressed in 7-34% of LMGC. Alpha-radioimmunotherapy (α-RIT) is expected to be a promising therapeutic option for metastasis with the combination of cancer specific drug delivery of antibody and high cell cytotoxicity of α-particle. Astatine 211 (At-211) is an attractive α-particle emitter with appropriate half-life and producible with cyclotron. We have investigated the therapeutic efficacy and toxicity of α-RIT with [At-211]-trastuzumab against LMGC using preclinical mice model. A single injection of [At-211]-trastuzumab effectively eradicated LMGC without recurrence in 6/8 mice and significantly prolonged the survival compared to control. There was no severe toxicity observed as long as we monitored. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第60回日本核医学会学術総会 | |||||
発表年月日 | ||||||
日付 | 2020-11-12 | |||||
日付タイプ | Issued |